Editorial: New Advances in Cardiorenal Syndrome

Laurent Calvier1,2*, Gábor Kökény3,4 and Ernesto Martinez-Martinez5,6

1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, United States, 2Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3Institute of Translational Medicine, Semmelweis University, Budapest, Hungary, 4International Nephrology Research and Training Center, Semmelweis University, Budapest, Hungary, 5Departamento de Fisiologia, Facultad de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain, 6Ciber de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain

KEYWORDS
cardiorenal syndrome, cardiovascular system, heart failure, kidney failure, inflammation, fibrosis, mitochondria, biomarker

Crosstalk between cardiovascular system and kidney becomes apparent when failure in one system adversely impacts the other in a negative loop. The term cardiorenal syndrome became more popular in the past 10 years and commonly refers to the collective dysfunction of heart and kidney resulting in a cascade of feedback mechanisms causing damage to both organs and is associated with adverse clinical outcomes. Indeed, a large number of patients with acute decompensated heart failure present with various degrees of heart and kidney dysfunction.

Recently, cardiorenal syndrome has been categorized into 5 clinical subtypes that reflect the pathophysiology, the timeframe, and the nature of concomitant cardiac and renal dysfunction (1). This clinical classification has raised interest on this condition, but its pathophysiology remains unclear and involves complex, multifactorial, and dynamic mechanisms. Some features are common in both heart failure and chronic kidney diseases, such as oxidative stress, inflammation and fibrosis leading to organ remodeling and dysfunction (2).

To study this syndrome, some mouse and rat models are available in which both cardiac and renal dysfunction are induced (3), but the translation of the results from animal studies to clinic is limited, highlighting the need for better models. In addition to rodent models and to circumvent interspecies limitations, Gabbin et al. reviewed in vitro options and advances mimicking the dynamic organ-organ crosstalk. For example, human induced pluripotent stem cells in combination with microfluidic chips represents a powerful tool with potential to recapitulate the characteristics of cardiorenal syndrome in vitro, thus offering a platform for therapy development. Human cohorts, animal models and human cell cultures together offer complementary approaches to study how complex hemodynamic, biochemical and hormonal factors contribute to
the development of the cardiorenal syndrome. Often neglected in this heart-kidney crosstalk, mitochondria rapidly sense and respond to a wide range of stress stimuli. Shi et al. reviewed in vitro and animal studies that have identified an important role of mitochondrial dysfunction in heart failure and chronic kidney disease. They also discuss the current research evidence supporting that mitochondrial dysfunction is involved in various types of cardiorenal syndrome.

The communication between the heart and kidneys mainly relies on hormones, cytokines and other biomarkers circulating in the blood. Consequently, efforts have been made to identify those markers and use them for diagnostic and treatment (1). Following this idea, Caravaca Perez et al. have associated Galectin-3, a well-known inflammatory marker (4–10), with high mortality in patients with acute HF and renal dysfunction. They also demonstrated that renal function influences the prognostic value of Galectin-3 levels, which should be adjusted by eGFR (estimated glomerular filtration rate) for a correct interpretation. Besides plasma or serum, urines biomarkers can be also measured as demonstrated by Diaz-Riera et al., using the urinary vitamin D binding protein (uVDBP), a multifunctional protein with major functions as binding/transport for all vitamin D metabolites but also fatty acid transport, and immune system (11). This protein is increased in patients with acute decompensated heart failure at hospital admission and presents a differential evolution pattern at early stage of renal dysfunction, before pathological worsening of glomerular filtration rate is evidenced.

In addition to biomarkers, clinical parameters are followed and used to evaluate the course of the disease. For example, Lai et al. suggested that chronic kidney disease is associated with an increased risk of reduced ejection fraction (HFrEF), which was related to higher all-cause mortality in patients with coronary artery disease undergoing percutaneous coronary intervention. In another study, Palazzuoli et al. as for them proposed that chronic kidney disease severity is related to adverse event occurrence, however, its impact may differ among different renal function trajectories and subtypes during hospitalization. Consequently, persistent deterioration and transient improvement of renal function appear to be the two patterns associated with increased risk.

Because it is a complex multifactorial disease, our knowledge on the cardiorenal syndrome is constantly improved, and so are our therapeutic strategies. Thereby, Minh et al. point that despite their widespread use in the congestive heart failure, the evidence for intravenous loop diuretic administration is not as robust as many other treatments for heart failure and its advantages may be outweighed by the substantial risk of electrolyte disturbances and worsening renal function. Further, there is no consensus on the time point for early starting of add-on therapy and for the preferred diuretic combination. In their design and rationale paper, the authors lay out a new clinical study, the diuretic resistance acute heart failure (DR-AHF) trial, to demonstrate the efficacy of the timely intense loop diuretic monotherapy and tolvaptan combination treatment in the early stage of congestive heart failure with renal dysfunction and provide the clinical evidence of diuretic resistance.

This collection of publications offers a sample of advances in the field of cardiorenal syndrome, from bench side to bed side. It covers cell culture models, cellular response to stress, biomarkers, clinical parameters and improvement of clinical practice. Further collections or review are still needed to improve our comprehension of this syndrome. For example, to cover the discovery and the biology of biomarkers emerging in related fields (4, 6, 12–17), which would help to better stratify the patients and propose tailored therapies; or to explore repositioning of known treatments in related cardio/vascular/kidney diseases (18–22), which would allow fast deployment and increase therapeutic options for patients.

Author contributions

LC wrote the editorial. GK and EM-M have revised it for interpretation and content. All authors contributed to the article and approved the submitted version.

Conflict of interest

LC is a co-shareholder of Reelin Therapeutics Inc. and co-inventor of a patent related to anti-Reelin strategies (Application Number: 15/763.047 and Publication Number: 20180273637).

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Savira I, Magarey R, Liew D, Reid C, Kelly DJ, Kompa AR, et al. Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol. (2020) 177:2506–22. doi: 10.1111/bjp.15065

2. Delgado-Valero B, Cachofeiro V, Martínez-Martínez E. Fibrosis, the bad actor in cardiorenal syndromes: mechanisms involved. Cells. (2021) 10:1824. doi: 10.3390/cells10071824

3. Liu S. Heart-kidney interactions: mechanistic insights from animal models. Am J Physiol Renal Physiol. (2019) 316:F974–F985. doi: 10.1152/ajprenal.00624.2017

4. Calvier L, Martínez-Martínez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. (2015) 3:59–67. doi: 10.1016/j.jchf.2014.08.002

5. Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Calvier L, Leroy C, Cachofeiro V, et al. Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens. (2018) 36:368–76. doi: 10.1097/HJH.0000000000001545

6. Calvier L, Miana M, Reboul P, Cachofeiro V, Martínez-Martínez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. (2013) 33:67–75. doi: 10.1161/ATVBAHA.112.300569

7. Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, et al. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes. (2016) 40:1034–8. doi: 10.1038/ijo.2016.19

8. Martínez-Martínez E, Ibarrola J, Calvier L, Fernández-Celis A, Leroy C, Cachofeiro V, et al. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS ONE. (2011) 6:e166272. doi: 10.1371/journal.pone.0166272

9. Martínez-Martínez E, Calvier L, Fernández-Celis A, Rossoom LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. (2015) 66:767–75. doi: 10.1161/HYPERTENSIONAHA.115.05876

10. Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Front Cell Mol Biol. (2020) 7:586. doi: 10.3389/fcmb.2020.00586

11. Bouillon R, Schuit F, Antonio L, Rantinlad F. Vitamin D binding protein: a historic overview. Front Endocrinol. (2020) 10:910. doi: 10.3389/fendo.2019.00910

12. Calvier L, Xian X, Lee RG, Sachardou A, Mineo C, Shaui PW, et al. Reelin depletion protects against atherosclerosis by decreasing vascular adhesion of leukocytes. Arterioscler Thromb Vasc Biol. (2021) 41:1309–18. doi: 10.1161/ATVBAHA.121.316009

13. Calvier L, Demuth G, Manouchehr N, Wong C, Sachardou A, Mineo C, et al. Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes. Sci Transl Med. (2020) 12:eeya7675. doi: 10.1126/scitranslmed.aay7675

14. Calvier L, Boucher P, Herr J, Hansmann G. LRP1 deficiency in vascular SMC leads to pulmonary arterial hypertension that is reversed by PPARγ activation. Circ Res. (2019) 124:1778–85. doi: 10.1161/CIRCRESAHA.119.315088

15. Martínez-Martínez E, Cachofeiro V, Rousseau E, Álvarez V, Calvier L, Fernández-Celis A, et al. Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Mol Cell Endocrinol. (2015) 411:20–7. doi: 10.1016/j.mce.2015.04.007

16. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Itígo C, Labat C, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension. (2012) 60:563–73. doi: 10.1161/HYPERTENSIONAHA.112.201699

17. López-Andrés N, Calvier L, Labat C, Fay R, Diez J, Benetos A, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. (2013) 61:120–9. doi: 10.1161/HYPERTENSIONAHA.112.201699

18. Németh A, Mózes MM, Calvier L, Hansmann G, Kokény G. The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3. BMC Nephrol. (2019) 20:245. doi: 10.1186/s12882-019-1431-a

19. Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P, et al. PPARγ Links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab. (2017) 25:1118–34.e7. doi: 10.1016/j.cmet.2017.03.011

20. Kokény G, Calvier L, Legchenko E, Chouvarine P, Mózes MM, Hansmann G. PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis beneficial role in pulmonary hypertension and cardiac/pulmonary fibrosis. Curr Opin Nephrol Hypertens. (2020) 29:171–9. doi: 10.1097/MNH.0000000000000580

21. Kokény G, Calvier L, Hansmann G, PPARγ and TGFβ-major regulators of metabolism, inflammation, and fibrosis in the lungs and kidneys. Int J Mol Sci. (2021) 22:10431. doi: 10.3390/ijms221910431

22. Hansmann G, Calvier L, Ribano MG, Chan SY. Activation of the metabolic master regulator PPARγ: a potential pioneering therapy for pulmonary arterial hypertension. Am J Respir Cell Mol Biol. (2020) 62:143–56. doi: 10.1165/rcmb.2019-0226PS